Bacteriophage therapy for treating A. baumannii infected wounds

Award Information
Agency:
Department of Defense
Branch
Defense Advanced Research Projects Agency
Amount:
$99,991.00
Award Year:
2009
Program:
STTR
Phase:
Phase I
Contract:
W81XWH-09-C-0164
Award Id:
90069
Agency Tracking Number:
A09A-026-0171
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
The Columbus Center, 701 E. Pratt Street, Baltimore, MD, 21202
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
005318758
Principal Investigator:
Alexander Sulakvelidze
Chief Scientist
(410) 625-2533
asulakvelidze@intralytix.com
Business Contact:
John Vazzana
President and CEO
(410) 625-3813
jvazzana@intralytix.com
Research Institute:
University of Florida
Brian Prindle
Division of Sponsored Research
P.O. Box 115500
Gainesville, FL, 32611 5500
(352) 392-3516
Nonprofit college or university
Abstract
Treatment of bacterial-infected wounds is one the most critical problems in modern medicine, and it presents one of the most significant challenges for US troops during combat operations. The management of bacteria in wounds is complicated by the existence of multidrug-resistant strains and mutants. Therefore, novel modalities for preventing and treating wound infections, one of which may be highly purified and characterized bacteriophage preparations, are required. Lytic phages (i.e., bacterial viruses that infect and lyse their specific bacterial hosts) have been used to treat bacterial infections since their discovery during the first decade of the 20th century. However, their therapeutic use gradually declined in the "Western World" after the advent of antibiotics. At the present time, there is renewed interest in phage-based prophylactic and therapeutic approaches because phages are active against multidrug-resistant, pathogenic bacterial strains and mutants. Our current application proposes to develop a potent lytic bacteriophage preparation/cocktail against A. baumannii - a major wound pathogen of particular concern to the US Army, and an increasingly important public health problem. In addition, we will develop two murine wound-infection models for future studies evaluating our A. baumannii phage cocktail's efficacy in treating A. baumannii wound infections.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government